CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation.

克利夫兰-（商业线）-Athersys，Inc。（纳斯达克股票代码：ATHX），一家开发用于重症监护适应症的MultiStem®（invimestrocel）细胞疗法和再生医学公司，宣布Samuel Tingle博士，外科医生和博士候选人在英格兰泰恩河畔纽卡斯尔的纽卡斯尔大学，已获得英国研究与创新医学研究委员会的资助，以探索Athersys的多干细胞疗法在肾移植前机器灌注过程中的潜在用途。

Machine perfusion refers to a technology used for limiting the damaging effects of removing and transporting kidneys prior to transplantation. It involves a machine that pumps fluid around the organ while it is outside the body, allowing for the potential therapeutic treatments to the kidney after donation..

机器灌注是指用于限制移植前移除和运输肾脏的破坏作用的技术。它涉及一种机器，当器官在体外时将液体泵入器官周围，允许在捐赠后对肾脏进行潜在的治疗。。

The funding is for a planned study at Newcastle University titled “Hollow-fiber bioreactor technology to explore mechanisms and delivery of cellular therapy during machine perfusion of donated human kidneys,” which seeks to better understand the mechanisms of action and identify an optimal delivery method for Multipotent Adult Progenitor Cells (MAPC®), the research grade equivalent of MultiStem cells, into the kidney.

该资金用于纽卡斯尔大学的一项名为“中空纤维生物反应器技术的计划研究，旨在探索捐赠人体肾脏机器灌注过程中细胞治疗的机制和实施”，旨在更好地了解作用机制并确定最佳的多能成体祖细胞（MAPC®），研究等级相当于多干细胞，进入肾脏。

Athersys and Newcastle University researchers previously demonstrated that administration of MAPC cells to donor human kidneys during machine perfusion resulted in healthier organs more suitable for transplantation..

Athersys和纽卡斯尔大学的研究人员先前证明，在机器灌注期间向供体人肾施用MAPC细胞导致更适合移植的更健康的器官。。

“We see the benefits of MAPC cell therapy as wide reaching because the processes that injure donated organs also occur in common medical situations such as heart attacks and strokes. The planned study builds on our previous collaboration which demonstrated the potential benefit of this therapy to treat human kidney ischemia/reperfusion injury ex vivo.

“我们认为MAPC细胞疗法的益处是广泛的，因为伤害捐赠器官的过程也发生在心脏病发作和中风等常见医疗情况下。计划的研究建立在我们之前的合作基础上，证明了这种疗法的潜在益处。离体治疗人肾缺血/再灌注损伤。

These data demonstrate that treatment with MAPC cell therapy is feasible when undertaken immediately following ischemic injury, which is the damage done to an organ when it is deprived of its blood flow, and that treatment improves function while simultaneously decreasing inflammation and markers of acute kidney injury.

这些数据表明，在缺血性损伤后立即进行MAPC细胞治疗是可行的，缺血性损伤是器官被剥夺血流时对器官造成的损害，并且该治疗改善了功能，同时减少了炎症和急性肾损伤的标志物。

We look forward to sharing our results with Athersys as we advance our understanding of how best to utilize these cells to improve kidney transplants,” said Dr. Tingle..

Tingle博士说，随着我们进一步了解如何最好地利用这些细胞改善肾脏移植，我们期待与Athersys分享我们的结果。。

“This planned study builds upon the foundation of several publications and early clinical work in solid organ transplant with collaborators. The findings from this research may also be highly relevant to our trauma program due to the potential for meaningful clinical benefit associated with MultiStem administration during the early phase of systemic inflammatory response.

“这项有计划的研究建立在几个出版物和早期临床工作的基础上，与合作者进行实体器官移植。这项研究的结果也可能与我们的创伤项目高度相关，因为在多个干细胞给药期间可能存在有意义的临床益处全身炎症反应的早期阶段。

MultiStem has the potential to improve the viability for transplant of these precious organs, leading to improved availability, reduced waiting times and renewed hope to patients on the waitlist,” said Dr. Sarah Busch, Vice President of Regenerative Medicine at Athersys..

Athersys再生医学副总裁Sarah Busch博士说，MultiStem有可能提高这些珍贵器官移植的可行性，从而提高可用性，减少等待时间并为等候名单上的患者带来新的希望。。

Learn more about Newcastle University here: https://www.ncl.ac.uk/.

在这里了解更多关于纽卡斯尔大学的信息：https://www.ncl.ac.uk/.

About MultiStem®

关于MultiStem®

MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage.

MultiStem®（invimestrocel）细胞疗法是临床开发中获得专利的再生医学产品，具有以各种方式促进组织修复和愈合的能力，例如通过响应炎症和组织信号产生治疗因子损伤。

MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique 'off-the-shelf' stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression.

多干细胞疗法对多维治疗效果的潜力将其与专注于单一益处机制的传统生物制药疗法区分开来。该疗法代表了一种独特的“现成”干细胞产品，可以以可扩展的方式制造，可以以冷冻形式储存多年，并且在没有组织匹配或需要免疫抑制的情况下施用。

Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need..

基于其疗效特征，其新的作用机制以及临床研究中证明的有利和一致的耐受性，我们认为多干细胞治疗可以为患者提供有意义的益处，包括患有严重疾病和未满足医疗需求的患者。。

About Athersys

关于阿瑟斯

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product.

Athersys是一家生物技术公司，致力于发现和开发旨在延长和提高人类生活质量的候选治疗产品。Athersys正在开发其MultiStem®细胞治疗产品，这是一种专利的成人衍生“现成”干细胞产品，最初用于神经系统，炎症和免疫以及其他重症监护适应症的疾病适应症，并且有几个正在进行的临床试验评估这种潜在的再生医学产品。

Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about Athersys on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms.

Athersys已经建立了战略合作伙伴关系和广泛的合作网络，以进一步推动多干细胞疗法向商业化方向发展。投资者和其他人应该注意，我们可以在我们的网站www.Athersys.com和/或我们在Twitter，Facebook，LinkedIn或其他社交媒体平台上的帐户上发布有关Athersys的信息。

It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in Athersys to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys.

帖子可能包含被视为材料信息的信息。因此，我们鼓励投资者，媒体和对Athersys感兴趣的其他人审查我们在www.Athersys.com网站上发布的信息以及我们的社交媒体帐户。请访问Twitter上的Athersys，网址为www.Twitter.com/Athersys。

Information that we may post about Athersys on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwi.

我们可能在我们的网站和/或Twitter，Facebook，LinkedIn或其他社交媒体平台上的帐户上发布有关Athersys的信息，可能包含1995年“私人证券诉讼改革法”含义内涉及风险的前瞻性声明和不确定性。您不应过分依赖我们网站上包含的前瞻性声明和/或Twitter，Facebook，LinkedIn或其他社交媒体平台上的我们帐户，我们不承担公开更新前瞻性声明的义务，无论是由于新信息，未来事件或其他原因。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the anticipated use of grant funding, the anticipated completion of any study or studies funded using grant funding, the anticipated outcome of any study or studies funded using grant funding, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events.

本新闻稿包含1995年“私人证券诉讼改革法”含义内涉及风险和不确定性的前瞻性陈述。这些前瞻性陈述除其他外，还涉及赠款资金的预期使用，任何使用赠款资金资助的研究或研究的预期完成情况，任何使用赠款资助资助的研究或研究的预期结果，我们的成长战略，以及我们未来的财务绩效，包括我们的运营，经济绩效，财务状况，前景，和其他未来事件。

We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations.

我们试图通过使用“预期”，“相信”，“可以”，“继续”，“可以”，“估计”，“期望”，“意图”，“可能”，“计划”，“潜力”，“应该”，“建议”，“意愿”或其他类似的表达方式来识别前瞻性陈述。这些前瞻性陈述只是预测，主要基于我们目前的预期。

In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risk that we will be unable to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern.

此外，一些已知和未知的风险，不确定性和其他因素可能会影响这些陈述的准确性。我们面临的一些更重要的已知风险是我们将无法筹集资金为近期和长期运营提供资金的风险，包括我们通过公共或私募股权发行获得资金的能力，债务融资，合作和许可安排或其他来源，根据我们或根本可以接受的条款，并继续作为持续关注。

The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations .

以下风险和不确定性可能导致我们的实际结果，活动水平，绩效或成就与这些前瞻性陈述所表达或暗示的任何未来结果，活动水平，绩效或成就大不相同：我们筹集资金为我们的运营提供资金。